Show simple item record

dc.contributor.authorOstermann, Lena
dc.contributor.authorMaus, Regina
dc.contributor.authorStolper, Jennifer
dc.contributor.authorSchutte, Lisanne
dc.contributor.authorKatsarou, Konstantina
dc.contributor.authorTumpara, Srinu
dc.contributor.authorPich, Andreas
dc.contributor.authorMueller, Christian
dc.contributor.authorJanciauskiene, Sabina
dc.contributor.authorWelte, Tobias
dc.contributor.authorMaus, Ulrich A.
dc.date2022-08-11T08:09:59.000
dc.date.accessioned2022-08-23T16:51:10Z
dc.date.available2022-08-23T16:51:10Z
dc.date.issued2021-02-08
dc.date.submitted2021-05-18
dc.identifier.citation<p>Ostermann L, Maus R, Stolper J, Schütte L, Katsarou K, Tumpara S, Pich A, Mueller C, Janciauskiene S, Welte T, Maus UA. Alpha-1 antitrypsin deficiency impairs lung antibacterial immunity in mice. JCI Insight. 2021 Feb 8;6(3):e140816. doi: 10.1172/jci.insight.140816. PMID: 33554955; PMCID: PMC7934856. <a href="https://doi.org/10.1172/jci.insight.140816">Link to article on publisher's site</a></p>
dc.identifier.issn2379-3708 (Linking)
dc.identifier.doi10.1172/jci.insight.140816
dc.identifier.pmid33554955
dc.identifier.urihttp://hdl.handle.net/20.500.14038/41807
dc.description.abstractAlpha-1 antitrypsin (AAT) is a major inhibitor of serine proteases in mammals. Therefore, its deficiency leads to protease-antiprotease imbalance and a risk for developing lung emphysema. Although therapy with human plasma-purified AAT attenuates AAT deficiency-related emphysema, its impact on lung antibacterial immunity is poorly defined. Here, we examined the effect of AAT therapy on lung protective immunity in AAT-deficient (KO) mice challenged with Streptococcus pneumoniae. AAT-KO mice were highly susceptible to S. pneumoniae, as determined by severe lobar pneumonia and early mortality. Mechanistically, we found that neutrophil-derived elastase (NE) degraded the opsonophagocytically important collectins, surfactant protein A (SP-A) and D (SP-D), which was accompanied by significantly impaired lung bacterial clearance in S. pneumoniae-infected AAT-KO mice. Treatment of S. pneumoniae-infected AAT-KO mice with human AAT protected SP-A and SP-D from NE-mediated degradation and corrected the pulmonary pathology observed in these mice. Likewise, treatment with Sivelestat, a specific inhibitor of NE, also protected collectins from degradation and significantly decreased bacterial loads in S. pneumoniae-infected AAT-KO mice. Our findings show that NE is responsible for the degradation of lung SP-A and SP-D in AAT-KO mice affecting lung protective immunity in AAT deficiency.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=33554955&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright: © 2021, Ostermann et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectBacterial infections
dc.subjectNeutrophils
dc.subjectProteases
dc.subjectPulmonology
dc.subjectAmino Acids, Peptides, and Proteins
dc.subjectBacterial Infections and Mycoses
dc.subjectImmunology and Infectious Disease
dc.subjectMolecular Biology
dc.subjectPulmonology
dc.subjectRespiratory Tract Diseases
dc.titleAlpha-1 antitrypsin deficiency impairs lung antibacterial immunity in mice
dc.typeJournal Article
dc.source.journaltitleJCI insight
dc.source.volume6
dc.source.issue3
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=5640&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/4609
dc.identifier.contextkey22982176
refterms.dateFOA2022-08-23T16:51:11Z
html.description.abstract<p>Alpha-1 antitrypsin (AAT) is a major inhibitor of serine proteases in mammals. Therefore, its deficiency leads to protease-antiprotease imbalance and a risk for developing lung emphysema. Although therapy with human plasma-purified AAT attenuates AAT deficiency-related emphysema, its impact on lung antibacterial immunity is poorly defined. Here, we examined the effect of AAT therapy on lung protective immunity in AAT-deficient (KO) mice challenged with Streptococcus pneumoniae. AAT-KO mice were highly susceptible to S. pneumoniae, as determined by severe lobar pneumonia and early mortality. Mechanistically, we found that neutrophil-derived elastase (NE) degraded the opsonophagocytically important collectins, surfactant protein A (SP-A) and D (SP-D), which was accompanied by significantly impaired lung bacterial clearance in S. pneumoniae-infected AAT-KO mice. Treatment of S. pneumoniae-infected AAT-KO mice with human AAT protected SP-A and SP-D from NE-mediated degradation and corrected the pulmonary pathology observed in these mice. Likewise, treatment with Sivelestat, a specific inhibitor of NE, also protected collectins from degradation and significantly decreased bacterial loads in S. pneumoniae-infected AAT-KO mice. Our findings show that NE is responsible for the degradation of lung SP-A and SP-D in AAT-KO mice affecting lung protective immunity in AAT deficiency.</p>
dc.identifier.submissionpathoapubs/4609
dc.contributor.departmentHorae Gene Therapy Center
dc.source.pagese140816


Files in this item

Thumbnail
Name:
140816.1_20210125110305_covere ...
Size:
2.084Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright: © 2021, Ostermann et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.
Except where otherwise noted, this item's license is described as Copyright: © 2021, Ostermann et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.